Clifford Chance advises Keymed Biosciences Inc. on out-licensing transaction with Belenos Biosciences

en
zh
Language options

13 August 2024

Yi Yang, Yong Bai, Dayu Man, , Annabel Joschko, Yuling Geng, , Andrew Epstein, , Matthew Warner, Daryl Fairbairn (He/Him), Lauren Rackow, Vicki Ye, Brian Concklin, Renée Latour (She/Her),
Singapore, Beijing, Düsseldorf, Hong Kong, New York, Shanghai, Washington D.C.

Clifford Chance advises Keymed Biosciences Inc. on out-licensing transaction with Belenos Biosciences

Global law firm Clifford Chance has advised Keymed Biosciences (Chengdu) Co., Ltd. on its out-licensing transaction with Belenos Biosciences, Inc.to exclusively develop, manufacture and commercialise Keymed's drug candidates, the bispecific antibodies CM512 and CM536 for global markets excluding Greater China. Bispecific antibodies are primarily used to treat a variety of diseases, particularly in the field of oncology and immunology.

As part of the transaction, iBridge HK Holdings Limited (a wholly-owned subsidiary of Keymed) will take a 30.01% equity interest in Belenos.

Shanghai partner Yang Yi said, "It's an honour advising Keymed on this strategic transaction which highlights our expertise in innovative, cross-border and IP-driven transactions in the healthcare sector."

Yi led a cross-border team of lawyers in Düsseldorf, Hong Kong, New York and Washington, D.C. advising on M&A, antitrust, intellectual property and equity investment aspects. The team comprised:

Beijing: Partner Bai Yong, counsel Dayu Man
Düsseldorf: Counsel Carolin Kemmner and associate Annabel Joschko;
Hong Kong: Counsel Yuling Geng, senior associate Michael Yan;
New York: Partners Andrew Epstein, Jason W. Parsont and Matthew Warner, counsel Daryl Fairbairn and Lauren Rackow and associate Vicki Ye; and
Washington D.C.: Partners Brian Concklin and Renee Latour and associate Elyssa Wenzel.

New York partner Matthew Warner said, "This transaction reflects the amazing, collaborative teams we have across the globe. It was a pleasure to work with our colleagues in Shanghai, Hong Kong and Germany to provide cohesive healthcare and US investment advice for Keymed on a transaction that will further strengthen its network and the value of its platform."

The firm has a track record of advising on landmark and innovative transactions in the healthcare and life sciences sector including advising Sciclone Pharmaceuticals on its HK$8.79 billion privatisation by GL Capital, Haier Group on the global regulatory filings for its acquisition of a 20% equity stake in blood products company Shanghai RAAS from Grifols and medical devices company MicroPort Scientific Corporation on its convertible loan facility and credit support.

高伟绅律师事务所就康诺亚授予Belenos Biosciences新药许可提供法律服务

国际律师事务所高伟绅就康诺亚生物医药科技（成都）有限公司与Belenos Biosciences, Inc.的许可交易提供法律服务。康诺亚通过许可协议授予Belenos在全球除中国大陆和港澳台以外区域开发、生产及商业化双特异抗体CM512及CM536的独家权利。双特异性抗体主要用于治疗各种疾病，尤其是肿瘤学和免疫学领域的疾病。

作为交易的一部分，一桥香港控股有限公司（康诺亚的全资子公司）将获得Belenos约30.01%的股权。

上海办公室合伙人杨毅表示：" 很荣幸能参与康诺亚的此次战略。这项跨境交易涉及股权、知识产权以及生命科学等多个领域，非常高兴能与本所各个领域的专家一起为康诺亚提供服务。

纽约办公室合伙人Matthew Warner表示：" 这项交易体现了我们拥有一支出色、协作的全球团队。很高兴能与本所中国办公室的同事合作，为康诺亚的交易提供生命科学与美国投资方面的法律服务。"

纽约办公室资深顾问律师Daryl Fairbairn表示：" 非常高兴能与康诺亚团队一起合作。他们充满热情以及朝气。能够为康诺亚的创新资产走向全球市场尽绵薄之力，我深感荣幸。"

本次交易的团队成员来自高伟绅上海、香港、纽约、华盛顿特区和杜塞尔多夫办公室，覆盖公司并购、反垄断、资本市场、监管合规、知识产权等多个领域，由中国合伙人杨毅和柏勇及纽约办公室合伙人Matthew Warner等领导。

本所在为医疗保健和生命科学领域具有里程碑意义的创新交易提供法律服务方面业绩突出，包括就赛生药业以87.9亿港元被德福资本私有化提供法律服务，就海尔集团向基立福收购血液制品公司上海莱士20%股权的全球监管备案为海尔集团提供法律服务，以及就医疗器械公司微创医疗科学的可转换贷款融资和信贷支持提供法律服务。